Company intelligence / Profile preview
VSPharmTech
Cambridge, MA, United Statesvspharmtech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
VSPharmTech is a clinical-stage biotech company focused on oncology, with its lead asset, VS‑101, an oral radiosensitizer currently in Phase II trials for head and neck cancer. The company has secured four IND approvals across Korea and the US and is developing three unlicensed anticancer drug candidates. It leverages technologies such as drug repurposing, real-world evidence, and artificial intelligence to optimize development[1][2][3].
- Therapeutic areas
- Oncology
- Modalities
- Small molecule (radiosensitizers, chemosensitizers)Designer drugs (as per patent filings)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
JLABS incubation by Johnson & Johnson[3]
Beyond the preview
Go deeper on VSPharmTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VSPharmTech.